Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.

被引:1
作者
Ho, A. L.
Bendell, J. C.
Cleary, J. M.
Schwartz, G. K.
Burris, H. A.
Oakes, P.
Agbo, F.
Barker, P. N.
Senderowicz, A. M.
Shapiro, G.
机构
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] AstraZeneca, Wilmington, DE USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
3033
引用
收藏
页数:1
相关论文
empty
未找到相关数据